Skip to main content
Premium Trial:

Request an Annual Quote

Predictive Oncology, Cancer Research Horizons to Study Glutaminase Inhibitors

NEW YORK – Predictive Oncology on Friday said it is using its machine learning platform to help Cancer Research Horizons advance the development of its glutaminase inhibitors to the clinic.

Cancer Research Horizons, a part of Cancer Research UK, is dedicated to drug discovery and development. In this latest partnership, Cancer Research Horizons will use Predictive Oncology's machine learning platform, called Pedal, to identify cancer types and patient populations most likely to respond to its glutaminase inhibitors.

"Ensuring that patients receive the right treatment for them is of paramount importance, and is why we are excited to work with Predictive Oncology to identify the most suitable population for further development of our compounds," said Tony Hickson, chief business officer at Cancer Research UK and Cancer Research Horizons. Cancer Research Horizons' glutaminase inhibitors are currently in the preclinical stage, but the organization is hoping to use the insights generated via the Pedal platform on tumor heterogeneity to increase their chances of success in clinical trials.

The Pedal platform pairs artificial intelligence capabilities with a privately held biobank of over 150,000 tumor samples. Predictive Oncology recently partnered with Cvergenx to develop a genomics- and machine learning-informed approach to personalized radiation therapy and oncology drug discovery.